Genmab A/S
Denmark · owned by Independent (Denmark) · www.genmab.com · 6 vendors
Genmab is an international biotechnology company that creates and develops innovative and differentiated antibody products with the purpose of improving the lives of people with cancer. The company is focused on the creation, development and commercialization of human antibody therapeutics for the treatment of cancer.
Resilience scores
- Digital Sovereignty: 0
- Digital Resilience: 8
Technology vendors
- Broadcom Inc. — Technology — United States
- Fortra — Technology — United States
- Salesforce, Inc. — Technology — United States
- and 3 more
Insights
Last updated 2026-09-13
6 direct vendors, 146 subvendors
Direct vendors by controlling owner country (sample)
- United States: 5
- Sweden: 1
Subvendors by controlling owner country (sample)
- Sweden: 2
- Japan: 1
- Czech Republic: 1
Migration Readiness: 5/10
Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.
Confidence: Low. The internal technology stack is not publicly disclosed. As a biotechnology company, Genmab's core competency is drug discovery, not software engineering. Their infrastructure likely consists of a hybrid environment with a mix of on-premise systems for laboratory equipment, specialized scientific software (COTS), and standard enterprise systems (e.g., SAP), combined with cloud services (IaaS/PaaS) for large-scale data analysis and storage. This typical setup for the industry suggests a moderate, but not native, cloud maturity. The score of 5 is a conservative estimate reflecting this uncertainty and the likely presence of legacy, specialized systems that are difficult to migrate.
Financials
Three-year financials
- 2025: revenue USD 3.72B, EBIT USD 1.06B, equity USD 5.85B
- 2024: revenue USD 3.12B, EBIT USD 972M, equity USD 5.14B
- 2023: revenue USD 2.39B, EBIT USD 772M, equity USD 4.69B
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.